What Abingworth does

Abingworth is a London-headquartered international life sciences investment group operating as a wholly owned subsidiary of The Carlyle Group following its August 2022 acquisition. The firm deploys capital across the full biopharmaceutical development lifecycle through a three-pillar platform: Seed & Early Stage venture investing (typical investment $15-$30m per company, 3-8 year hold, primarily US and Europe); Development Stage investing via its proprietary VIPEs (Venture Investments in Public Equities) approach; and Clinical Co-Development (CCD) partnerships with pharma and biotech companies for pivotal-stage biotherapeutics (minimum $30m per deal, often structured as hybrid equity plus development financing, 2-10 year hold). Since its first biotech investment in 1987, Abingworth has backed 190-201 life science companies across biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, and cell therapies, operating from offices in London, New York, and San Francisco with team coverage in Boston.

Revenue mechanics combine recurring management fees on committed fund capital with performance-based carried interest on exits. The firm has raised 15 dedicated life sciences funds, with the three most recent vehicles — Abingworth Bioventures 8 ($465m, 2020 vintage), Clinical Co-Development Fund 2 ($582m, 2021), and the Clinical Co-Development Co-Investment Fund ($356m, 2023) — representing the bulk of current investable capital. Notable CCD transactions include up to $210m for Gilead Sciences' Trodelvy ADC, $150m for Pathalys Pharma's upacicalcet, and $100m non-dilutive financing for CymaBay's seladelpar. The CCD strategy is operationally executed through Launch Therapeutics, Abingworth's dedicated clinical co-development vehicle.

The firm's reported outcomes include 36 product approvals since 2012, 75 IPOs, 53 M&A exits, and 17 CCD deals completed. Customer concentration is low across both LP capital (spread across 15 funds and multiple vintages) and portfolio companies (190-201 diversified positions). Recent deal flow into 2025-2026 spans co-led Series rounds in Cytospire, AdvanCell, R1 Therapeutics, and cAMPfield Therapeutics, plus major CCD collaborations with Gilead and Teva, indicating continued strong deal cadence under Carlyle ownership.

Name

Abingworth

Legal name

Abingworth LLP

Website

https://abingworth.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

11–50 employees

Short description

Abingworth is a London-based life sciences investment group and wholly owned subsidiary of The Carlyle Group, managing 15 dedicated funds across seed, venture, public equity (VIPEs), and Clinical Co-Development strategies to back biotech entrepreneurs globally.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Vehicles (525990)

SIC

Investment Advice (6282)

akta.pro primary industry

Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

Keywords

• Life sciences venture capital
• Biotech venture investing
• Clinical co-development financing
• Healthcare private equity
• Biopharma investment funds

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Fund Management Fees: Abingworth raises dedicated life sciences funds (15 funds to date including Bioventures 1-8, Clinical Co-Development 1 & 2, and CCD Co-Investment Fund) and earns management fees on assets under management. Most recent venture fund Abingworth Bioventures 8 raised $466 million; Clinical Co-Development Fund 2 raised $466 million; Clinical Co-Development Co-Investment Fund raised $356 million.
2. Carried Interest / Investment Returns: Earns carried interest (performance-based returns) from successful exits across the portfolio. Abingworth has achieved 36 product approvals since 2012, 75 IPOs, and 53 M&A exits, generating returns from successful biotech investments.
3. Clinical Co-Development Funding: Provides structured development financing (minimum $30m per company, often combined with equity in hybrid financing solutions) to pharmaceutical and biotech companies for pivotal-stage biotherapeutics, seeking accelerated return through monetisation.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Abingworth is a life sciences investment firm that manages 15 dedicated life sciences funds across three core strategies: Seed & Early Stage venture investing (typical investment $15-$30 million per company), Development Stage including the firm's pioneering VIPEs (Venture Investments in Public Equities), and Clinical Co-Development (minimum $30 million per company for pivotal-stage biotherapeutics). The firm invests in biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, and platform technologies from offices in London, New York, and San Francisco, deploying both venture capital and structured hybrid financing solutions to biotech entrepreneurs on both sides of the Atlantic.

Product overview

Abingworth is a life sciences investment firm (now part of The Carlyle Group since August 2022) that operates a multi-pronged investment platform rather than a single product. Its core offering consists of approximately 15 dedicated life sciences and healthcare funds organized around three broad strategic pillars: Seed & Early Stage venture investing (exemplified by Abingworth Bioventures VI, VII, and VIII, the latest being ABV 8 which raised $466 million in 2020); Development Stage investing including the firm's pioneering VIPEs (Venture Investments in Public Equities) approach; and Clinical Co-Development (exemplified by CCD 1 launched in 2016, CCD 2 raised in 2021, and the CCD-CIF raised in 2023 at $356 million), which partners with pharmaceutical and biotech companies to fund pivotal-stage clinical trials. Across these strategies, Abingworth invests in biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, specialty pharma, and platform technologies, with typical venture investment sizes of $15-$30 million and minimum $30 million for clinical co-development deals. Abingworth has invested in over 190 life science companies since its founding and operates from offices in London, New York, and San Francisco.

Differentiator

Problem solved

Functional benefit

Products and services

• Abingworth Bioventures 8 (ABV 8) Abingworth's most recent venture fund, vintage 2020, with $466 million dedicated to seed and early-stage life sciences investments across the US and Europe. Holds 16 portfolio companies. Typical investment size $15-$30 million per company with a 3-8 year holding period.
• Clinical Co-Development 2 (CCD 2) Pivotal-stage biotherapeutics financing fund raised in 2021 with $582 million, designed to partner with pharmaceutical and biotech companies to help develop effective new drugs and deliver them to patients in an accelerated manner through hybrid equity/financing solutions. Holds 4 portfolio companies.
• Clinical Co-Development Co-Investment Fund (CCD-CIF) Pivotal-stage biotherapeutics co-investment fund raised in 2023 with $356 million, investing alongside the flagship CCD 2 vehicle. Holds 3 portfolio companies and is actively investing in late-stage biotherapeutics.
• Clinical Co-Development 1 (CCD 1) Abingworth's first Clinical Co-Development fund launched in 2016, pioneering a new approach to partnering with pharmaceutical and biotech companies to fund expensive clinical trials through hybrid financing structures. Holds 16 portfolio companies.
• Abingworth Bioventures VII (ABV 7) Venture fund with $315 million for seed and early-stage life science investments, vintage 2017. Holds 23 portfolio companies across the US and Europe.
• Abingworth Bioventures VI (ABV VI) Venture fund raised in 2012 for life sciences investments. Holds 25 portfolio companies, the largest among Abingworth's venture funds.

Quantifiable outcome

• 36 product approvals since 2012
• +5 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered minor, major and flagship.

• Jeito CapitalminorOthers · 1 May 2026Sarah Shackelton, who joined Jeito Capital as Partner, Talent, previously worked at Oxford Science Enterprises and Abingworth, bringing expertise in building senior leadership teams for VC-backed life sciences companies.
• Alebund PharmaceuticalsminorStrategic or Co-development Partner · 1 March 2026Alebund Pharmaceuticals entered into a licensing and equity agreement with Abingworth-backed R1 Therapeutics, granting exclusive rights to develop, manufacture, and commercialize the kidney disease drug AP306 outside Greater China. The collaboration includes potential milestone payments of up to low triple-digit millions of US dollars and tiered royalties in low double-digit percentages.
• Launch TherapeuticsmajorStrategic or Co-development Partner · 1 January 2026Launch Therapeutics is Abingworth's strategic development partner for clinical co-development deals, including the Pathalys Pharma collaboration to advance upacicalcet and the Teva dual-action asthma rescue inhaler program. Launch Therapeutics is a key vehicle for Abingworth's CCD strategy.
• Eli LillymajorStrategic or Co-development Partner · 1 February 2025Abingworth portfolio company AdvanCell entered into a strategic collaboration with Lilly to advance novel targeted alpha therapies for the treatment of cancer, announced in February 2025.
• Teva PharmaceuticalmajorStrategic or Co-development Partner · 1 September 2024Clinical collaboration agreement established between Teva and Abingworth-backed Launch Therapeutics to accelerate development of dual-action asthma rescue inhaler (ICS-SABA/TEV-'248) respiratory program, with Abingworth entering a strategic development funding agreement.
• Pathalys PharmamajorStrategic or Co-development Partner · 1 January 2023Abingworth led $150 million secured product financing and equity for Pathalys Pharma to advance upacicalcet through pivotal Phase 3 studies, forming a strategic collaboration with Launch Therapeutics. Pathalys Pharma subsequently raised $105 million Series B Financing in August 2024.
• The Carlyle GroupflagshipStrategic or Co-development Partner · 1 August 2022Carlyle completed its acquisition of Abingworth in August 2022, expanding Carlyle's global healthcare franchise with Abingworth's leading life sciences investment expertise. As part of The Carlyle Group, Abingworth operates as its life sciences investment platform. Carlyle's then-CEO Harvey Schwartz noted the strategic value of Abingworth's life sciences franchise.

Scale indicators16 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• OrbiMed: One of the largest dedicated healthcare/life-sciences investment firms globally, investing across venture, growth, public equity, and structured finance stages. Directly comparable to Abingworth's multi-strategy life-sciences platform and similar transatlantic footprint.
• Atlas Venture: Early-stage life-sciences venture firm building biotech companies from inception, with offices in Cambridge, MA and London. Closely comparable to Abingworth's seed/early-stage strategy and transatlantic biotech focus.
• SV Health Investors: Healthcare and life-sciences focused venture and growth investor with biotech, medtech, and healthcare services strategies. Comparable multi-strategy life-sciences platform; recently co-led with Abingworth on AdvanCell Series C.
• Frazier Life Sciences: Dedicated life-sciences investment firm investing across public and private biotech stages. Comparable to Abingworth's Bioventures and VIPEs strategies; led the cAMPfield Series A in which Abingworth participated.
• 5AM Ventures: Early-stage life-sciences venture firm with offices in San Francisco and Boston focused on building biotech companies from inception. Comparable seed/early-stage biotech focus to Abingworth Bioventures.
• Versant Ventures: Healthcare-focused venture firm with presence in US, Canada, and Europe investing across biotech, medtech, and healthcare services. Comparable early-to-growth biotech investing model.
• ARCH Venture Partners: Large early-stage life-sciences and technology venture firm focused on founding and seeding biotech companies. Comparable seed/early-stage biotech focus with strong track record of biotech venture creation.
• Deerfield Management: Healthcare-focused investment firm with venture, growth, public equity, and structured financing strategies. Comparable multi-strategy life-sciences platform to Abingworth's Bioventures + CCD + VIPEs combination.
• Forbion: European life-sciences venture capital firm investing across biotech stages with offices in Netherlands and Germany. Closely comparable to Abingworth's European biotech focus; participated alongside Abingworth in cAMPfield Series A.
• RA Capital Management: Healthcare-focused investment manager operating a crossover fund that invests in public and private biotech companies. Comparable to Abingworth's public/private crossover approach (VIPEs) and participated in cAMPfield Series A alongside Abingworth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/abingworth
• Xx.com/abingworthbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments198 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abingworth